ReviewMaedica2025
Current Knowledge of Neonatal Birth Asphyxia - a Review of Recent Literature and Novel Approach.
Review in Maedica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Acute Perinatal Hypoxia Impairs Neurobehavioral Development and Increases Basilar Artery Contractility in Adult Male Rats.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
As neonatal intensive care has developed, there has been a growing focus on reducing mortality and morbidity. Hypoxic-ischemic injury remains the primary cause of neonatal brain dysfunction. Recently, notable advancements have been made in neuroprotection, particularly with the introduction of therapeutic hypothermia. Furthermore, identifying specific biomarkers has constituted another significant advance in neuroprotection, allowing clinicians to screen infants for brain injury, monitor disease progression, identify affected regions and assess the efficacy of neuroprotective trials. Erythropoietin (EPO) has demonstrated potential in the treatment of perinatal hypoxia, particularly in the reduction of neurological damage and improvement of outcomes in neonates with hypoxic-ischemic encephalopathy. While further research is required to ascertain the optimal usage, the existing evidence suggests that EPO could be a valuable component of a comprehensive treatment plan, potentially in conjunction with therapeutic hypothermia.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.